Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha.
暂无分享,去创建一个
[1] S. Yamaguchi,et al. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. , 1998, Journal of molecular and cellular cardiology.
[2] V. Adabayeri,et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria , 1998, The Lancet.
[3] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[4] H. Figulla,et al. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. , 1998, International journal of cardiology.
[5] C. Holt,et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.
[6] E. Olasz,et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. , 1997, Journal of immunology.
[7] A. Koretsky,et al. Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .
[8] Wei Wu,et al. Identification and functional characterization of a second chain of the interleukin‐10 receptor complex , 1997, The EMBO journal.
[9] S. Yamaguchi,et al. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. , 1997, Japanese circulation journal.
[10] M. Caligiuri,et al. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. , 1997, Blood.
[11] T. van der Poll,et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. , 1997, Journal of immunology.
[12] M. Lazarus,et al. An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[13] P. Iversen,et al. Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. , 1997, Cancer research.
[14] J. Darnell,et al. Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain* , 1996, The Journal of Biological Chemistry.
[15] T. LeJemtel,et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.
[16] A. Kumar,et al. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. , 1996, Journal of immunology.
[17] C. Meisel,et al. Differential regulation of monocytic tumor necrosis factor‐α and interleukin‐10 expression , 1996, European journal of immunology.
[18] O. Moine,et al. Adenosine enhances IL-10 secretion by human monocytes. , 1996, Journal of immunology.
[19] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[20] D. Mann,et al. Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .
[21] T. van der Poll,et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.
[22] A. Dalgleish,et al. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. , 1995, Heart.
[23] O. Febo,et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.
[24] A. Matsumori,et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.
[25] M. Feldmann,et al. Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.
[26] R. Schreiber,et al. Lipopolysaccharide-dependent induction of IL-10 receptor expression on murine fibroblasts. , 1994, Journal of immunology.
[27] M. Feldmann,et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis , 1994, The Journal of experimental medicine.
[28] P. Vandenabeele,et al. Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.
[29] S Sasayama,et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. , 1994, Circulation.
[30] R. de Waal Malefyt,et al. Expression cloning and characterization of a human IL-10 receptor. , 1994, Journal of immunology.
[31] L. Vaca,et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.
[32] S. Narula,et al. Characterization of interleukin-10 receptors on human and mouse cells. , 1993, The Journal of biological chemistry.
[33] G. Morris,et al. Tumour necrosis factor alpha in severe congestive cardiac failure. , 1993, British heart journal.
[34] Simon C Watkins,et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.
[35] L. Moldawer,et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] Y. Vodovotz,et al. Macrophage deactivation by interleukin 10 , 1991, The Journal of experimental medicine.
[37] T. Mosmann,et al. IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.
[38] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.
[39] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[40] A. Dalgleish,et al. Abnormal cytokine profiles inpatients with idiopathic dilated cardiomyopathy andtheir asymptomaticrelatives , 2011 .
[41] K. Chung,et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.